NEW YORK (GenomeWeb News) – Business information firm Thomson Reuters has bought GeneGo for an undisclosed sum in order to expand its healthcare and life sciences portfolio.
GeneGo, which provides bioinformatics tools for use in drug target selection and validation, biomarker identification, and patient profiling, has become part of Thomson Reuters' Healthcare & Science business segment.
"There is an increasing need for biology content, detailed disease insights, and analytics to support R&D productivity and to enable a more personalized approach to medicine," Jon Brett-Harris, executive vice president at Thomson Reuters, said in a statement Monday.
GeneGo is headquartered in San Diego and has offices in Moscow and in St. Joseph, Mich.
The firm's flagship system is the MetaCore, which provides analysis for microarray gene expression studies, SNPs, metabolic profiles or high-content screening assays. The firm's offerings also include the MetaBase mammalian biology and medicinal chemistry database, and the MetaDrug systems pharmacology platform that can be used to predict human metabolites, toxicity, and mode of action of novel small molecule compounds.
Financial terms of the agreement were not released.
GeneGo said recently that it has integrated its MetaCore solution with Agilent's GeneSpring offering for use in analyzing and handling microarray data, and last month said that it has integrated the MetaCore and MetaDrug products with GenomeQuest's Sequence Data Management platform.